Condition: Amyotrophic Lateral Sclerosis · Sponsor: Haukeland University Hospital
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK (Norwegian kroner) per year. Research i.a. from the investigators department has shown that increased activity in histone deacetylation enzymes (sirtuins) together with increased access to Nicotinamide Adenine Dinucleotide (NAD) can delay disease progression. Nicotinamide riboside (NR) can increase cells' access to NAD and Pterostilbene will stimulate sirtuins. The investigators want to study whether combination therapy with NR and Pterostilbene can inhibit neurodegeneration in ALS and thereby delay disease development, increase survival and improve quality of life in ALS. In the NO-ALS extension study the investigators will follow the patients who completed the original NO-ALS study. Objectives are to evaluate adverse events and give patients possibility of compassionate use, and secondarily to see if the combination of NR and pterostilbene (EH301) will decrease progression of motor symptoms and loss of vital capacity, and increase survival time in patients with ALS.
This description comes directly from the study's public registry record.
Ole-Bjørn Tysnes · +4755975063 · obty@haukeland.no
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital | Bergen, Norway | Recruiting |
| Nordlandssykehuset HF | Bodø, Norway | Not Yet Recruiting |
| Vestre Viken HF | Drammen, Norway | Not Yet Recruiting |
| Helse Førde HF | Førde, Norway | Not Yet Recruiting |
| Helse Fonna HF | Haugesund, Norway | Not Yet Recruiting |
| Sørlandet sykehus | Kristiansand, Norway | Not Yet Recruiting |
| Sykehuset Innlandet HF | Lillehammer, Norway | Not Yet Recruiting |
| Akershus University Hospital | Lørenskog, Norway | Not Yet Recruiting |
| Helse Møre og Romsdal | Molde, Norway | Not Yet Recruiting |
| Helse Nord-Trøndelag HF | Namsos, Norway | Not Yet Recruiting |
| Oslo Univerity Hospital | Oslo, Norway | Not Yet Recruiting |
| Sykehuset Østfold HF | Sarpsborg, Norway | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05095571